Novavax (NVAX) is a little biotech that has a long history. Multitudes of investors have thrown up their hands selling out of the stock in disgust. Nonetheless, Novavax still has a cohort of strong supporters. This posting evaluates the opposing issues.

While Novavax has positive possibilities, it is not a good candidate for new money. Even at its current low price, as an investor, I am tempted to sell out my small stake.

Novavax essentials remain fixed.

I last checked in on Novavax in early March 2018. My March 5, 2018 posting, "Novavax: Mounting Delays Raise Concerns" discussed both of Novavax's two marquee programs, RSV F for maternal vaccination and NanoFlu™.

READ FULL ARTICLE HERE